World News – AU – Policy of Vaccine


. .

The government must be open in the run-up to the vaccination drive, but the opp must also act with the same responsibility

India’s planned vaccination campaign against the coronavirus has understandably aroused a lot of curiosity, controversy, questions and fears. And at this stage of the pandemic, as the nation is challenged by wave attacks from the mutant virus and our health systems are worn down to contain the spiral, the deadliest threat comes not so much from the disease itself, but from misinformation. It is therefore of paramount importance that we follow science and transparency, seek an accurate bullet point rather than claiming human achievement, and send out the right kind of public service message. Certainly we can abolish it without politicizing the vaccination process, be it through the government trying to curb its excessive ambition or through the opposition questioning every step just to do so. In releasing two emergency vaccines – Covishield from the Serum Institute and Covaxin from Bharat Biotech – the government is apparently assuming that their effectiveness and immunogenicity, while not yet fully established, are still in the testing stage but are safe enough administered and good enough to provoke combat reactions in a large part of the population, break the chain of transmission and build herd immunity. Every nation is betting on it and our reviewers are still looking for dates for the vaccines that are legal even in the West. The drug agency has built in checks and balances that make emergency approval conditional on developers submitting progress details and side effects every two weeks. In addition, each person receiving the dose is monitored and their responses are updated as if they were in “clinical trial mode”. . Regarding the use of Covaxin, which is still awaiting data from its ongoing clinical trials, the government and the Indian Council for Medical Research (ICMR) are repeatedly making it clear that it is a replacement vaccine and the first series to be launched , be it the Serum Institute, which has made advances in studies and results. Health Minister Harsh Vardhan himself said that vaccines approved worldwide based on genes that code for spike proteins have a protective effect of over 90 percent. Covaxin – which is based on the entire inactivated virus – has other antigenic epitopes in addition to spike protein. So it’s likely that it has a similar protective effect, even for the new strain that emerged in the US. However, the fact is that the guesswork is not good enough and the government should immediately prioritize an information dissemination system that includes experts, not bureaucrats, to ensure transparency. Suppressing information could be risky, as the effectiveness of the vaccine can be different in different people and gene pools, as can its side effects. The fact that the government had not asked questions when authorizing the use of the vaccine therefore failed somewhat, exposing them to opposition charges of opacity on a sensitive issue, similar to what happened in Russia and China. It is good to clarify that the proposed dosage regimen is still in the works and could be changed depending on the shift in data interpretation.

There should be systematic myth-busting and detailed logs for side effects to remove fears and doubts. People need to be clear about what can also go wrong and how this can also be easily done. Without this interactivity, there will still be a lack of trust. The government’s challenge is to treat a complex issue with sensitivity, maturity, and a certain simplicity at the same time. Of course, the same responsibility is expected from the opposition. We could certainly have done without the reaction of the head of the Samajwadi Party (SP), Akhilesh Yadav, who said he would not choose to be vaccinated just because he did not believe in a « BJP vaccine ». . Or Congress will doubt the locally developed Covaxin and make an effort made by the best minds in the nation. The vaccine was already used in the preliminary round in children over 12 years of age and declared safe. The third level trials are running on the largest sample size and it could actually turn out to be our aatmanirbhar asset. The questions that the opposition actually has to ask concern the question of how a central plan is implemented neutrally in states, especially in states without a BJP, using a general election-like apparatus. Kerala has already argued that given its highest peak since the outbreak and the fact that a large portion of its population suffers from comorbidities, priority should be given to vaccine allocation. How much of the cost is shared between the center and the states? Who will ensure quality, demarcate populations, and who will have this new public health data? In the end, public health issues become political, and this is the greatest challenge we face.

Vaccine, Government

World News – AU – Politics of Vaccine



Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]